News

Marksans Pharma has received affirmation in credit ratings for bank facilities at IND AA-/ IND A1+ while outlook has been revised to `Positive` from `Stable`.

Marksans Pharma announced that it has entered into a definitive agreement to acquire 100% of the share capital of QliniQ B.V., a profitable Netherlands-based pharmaceutical company with established front-end sales, marketing, and distribution capabilities across the Dutch healthcare market. The acquisition marks a strategic step in expanding Marksans` presence across regulated European markets and strengthening its forward-integration strategy through direct, owned market-access capabilities in the European Union. QliniQ operates a differentiated portfolio of niche pharmaceuticals and medical devices, with established positions across women`s health, dermatology, respiratory care, and other specialty categories. The company has developed long-standing relationships across wholesalers, pharmacies, hospitals and insurer led tender channels in the Netherlands, supporting sustainable market access and growth. For the financial year ended 31 December 2025, QliniQ reported revenue of �9.35 million and net profit of �1.01 million. The company has delivered strong profitable growth, with revenue increasing at a CAGR of approximately 41% between FY2023 and FY2025, while maintaining a debt-free balance sheet.

Net profit of Marksans Pharma rose 63.59% to Rs 148.13 crore in the quarter ended March 2026 as against Rs 90.55 crore during the previous quarter ended March 2025. Sales rose 20.84% to Rs 856.11 crore in the quarter ended March 2026 as against Rs 708.46 crore during the previous quarter ended March 2025.For the full year,net profit rose 9.81% to Rs 417.90 crore in the year ended March 2026 as against Rs 380.58 crore during the previous year ended March 2025. Sales rose 12.51% to Rs 2950.94 crore in the year ended March 2026 as against Rs 2622.85 crore during the previous year ended March 2025. ParticularsQuarter EndedYear EndedMar. 2026Mar. 2025% Var.Mar. 2026Mar. 2025% Var. Sales856.11708.46 21 2950.942622.85 13 OPM %22.8317.92 -20.3620.31 - PBDT224.29138.84 62 659.19587.35 12 PBT200.00116.09 72 560.56503.97 11 NP148.1390.55 64 417.90380.58 10 Powered by Capital Market - Live News

Marksans Pharma announced that the Board of Directors of the Company at its meeting held on 26 May 2026, inter alia, have recommended the final dividend of Rs 0.9 per equity Share (i.e. 90%) , subject to the approval of the shareholders.

Marksans Pharma has granted 3 lakh stock options to certain eligible employees of the Company and its subsidiaries under Marksans Employees Stock Option Scheme 2024.